AUA 2025, bladder cancer, non-muscle invasive bladder cancer (NMIBC), PIVOT-006 trial, Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate-Risk non-muscle invasive bladder cancer, BCG-unresponsive non-muscle invasive bladder cancer, SUO-CTC trial.
STAT spoke with people living through the historic disruptions threatening the future of biomedical research in the U.S. These are their stories
AUA 2025 single-port vs multi-port robotic surgery, minimally invasive surgery, endourology, robot assisted laparoscopic radical prostatectomy, robot assisted partial nephrectomy.
AUA 2025 advanced prostate cancer, discrepancy between the CHAARTED and LATITUDE risk categories, metastatic hormone-sensitive prostate cancer (mHSPC).
AUA 2025 PIONEER+ Big Data Consortium, prostate cancer, systemic treatment prescription and switch patterns, metastatic hormone-sensitive prostate cancer (mHSPC) patients.
A closely watched clinical trial testing what could be the world’s first new tuberculosis vaccine in a century has hit its enrollment target, ahead of…
AUA 2025 HER2-overexpressing upper tract urothelial carcinoma, disitamab vedotin, toripalimab, Radical nephroureterectomy, surgery for urothelial carcinoma.
AUA 2025 Sequencing Therapy after BCG Failures, full-dose BCG induction course, blue light TURBT, high-risk NMIBC, gemcitabine-docetaxel, pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept.
The Department of Health and Human Services (HHS) and Secretary Robert F. Kennedy Jr. | As concerns about infectious disease outbreaks increase, the HHS is…
While there have been reports from drugmakers about possible interruptions with FDA matters due to staff layoffs, one company “hasn’t noticed any difference.”
